PUBLISHER: 360iResearch | PRODUCT CODE: 1611313
PUBLISHER: 360iResearch | PRODUCT CODE: 1611313
Respiratory Infection Diagnostics Market by Test (Antigen Detection Assays, Direct Fluorescent Antibody Tests, Imaging Tests), Disease (Asthma, Chronic Obstructive Pulmonary Disease, Coronavirus Infections), End-User - Global Forecast 2025-2030
The Respiratory Infection Diagnostics Market was valued at USD 76.94 billion in 2023, expected to reach USD 82.35 billion in 2024, and is projected to grow at a CAGR of 7.15%, to USD 124.78 billion by 2030.
The respiratory infection diagnostics market encompasses tools and methodologies used to diagnose diseases such as influenza, pneumonia, tuberculosis, and COVID-19, among others. The scope involves identifying causative pathogens-viruses, bacteria, and fungi-using technologies like polymerase chain reaction (PCR), rapid antigen tests, and serology. The necessity of respiratory infection diagnostics is underscored by the prevalence and spread of infections, which pose significant public health concerns, especially in densely populated and immunocompromised regions. Applications span clinical settings, research institutions, and home testing kits, highlighting the market's wide end-use spectrum. Key factors influencing growth include heightened awareness and demand for rapid diagnostics, technological advances, and rising incidences of infectious diseases. The recent advancement in digital health technology and artificial intelligence presents potential opportunities for businesses, enabling more precise diagnosis and facilitating personalized medicine approaches. Companies are recommended to invest in portable and rapid testing solutions, digital integration, and automation to meet the growing demand. However, the market faces limitations such as high costs associated with advanced diagnostics, regulatory approval challenges, and the need for highly skilled personnel. These factors can restrict market penetration, particularly in developing regions. Businesses must navigate these challenges by focusing on cost-effective yet reliable solutions. Additionally, there is an ongoing need for improved diagnostic accuracy and speed, representing viable areas for innovation, such as developing integrated point-of-care (POC) testing devices and leveraging machine learning algorithms for better data interpretation. The respiratory infection diagnostics market is competitive and rapidly evolving, with a strong focus on innovation, thereby presenting a robust opportunity for companies that can strategically address existing barriers. The market's dynamic nature requires staying abreast of current trends and technological advancements to remain competitive and meet global healthcare needs efficiently.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 76.94 billion |
| Estimated Year [2024] | USD 82.35 billion |
| Forecast Year [2030] | USD 124.78 billion |
| CAGR (%) | 7.15% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Infection Diagnostics Market
The Respiratory Infection Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Rising incidences of chronic obstructive pulmonary disease (COPD)
- Increasing healthcare infrastructure coupled with the availability of diagnostic procedures
- Rapid rise in government funding towards infectious disease diagnostics
- Market Restraints
- High cost of diagnosis and testing limited reimbursement scenarios
- Market Opportunities
- Availability of next-generation sequencing-based platform to diagnose respiratory tract infections
- Expanding number of R&D activities
- Market Challenges
- Strict regulatory constraints
Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Infection Diagnostics Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Infection Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Respiratory Infection Diagnostics Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Infection Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Infection Diagnostics Market
A detailed market share analysis in the Respiratory Infection Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Infection Diagnostics Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Infection Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Infection Diagnostics Market
A strategic analysis of the Respiratory Infection Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Respiratory Infection Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co. Ltd., Atomo Diagnostics Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioMerieux SA, BIORON Diagnostics GmbH, Cardinal Health Inc., Chembio Diagnostics, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Merck KGaA, Meridian Bioscience Inc. by SD Biosensor, Quest Diagnostics Incorporated, and Quidel Corporation.
Market Segmentation & Coverage
This research report categorizes the Respiratory Infection Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Test, market is studied across Antigen Detection Assays, Direct Fluorescent Antibody Tests, Imaging Tests, In Vitro Diagnostics (IVD) Tests, Nucleic Acid Amplification Tests, and Rapid Diagnostic Tests. The Imaging Tests is further studied across CT- Scan and X-ray.
- Based on Disease, market is studied across Asthma, Chronic Obstructive Pulmonary Disease, Coronavirus Infections, Enterovirus, Influenza diseases, Lung Cancer, Pneumonia, Tuberculosis, and Whooping Cough (Pertussis).
- Based on End-User, market is studied across Clinical Laboratories and Hospitals.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidences of chronic obstructive pulmonary disease (COPD)
- 5.1.1.2. Increasing healthcare infrastructure coupled with the availability of diagnostic procedures
- 5.1.1.3. Rapid rise in government funding towards infectious disease diagnostics
- 5.1.2. Restraints
- 5.1.2.1. High cost of diagnosis and testing limited reimbursement scenarios
- 5.1.3. Opportunities
- 5.1.3.1. Availability of next-generation sequencing-based platform to diagnose respiratory tract infections
- 5.1.3.2. Expanding number of R&D activities
- 5.1.4. Challenges
- 5.1.4.1. Strict regulatory constraints
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Respiratory Infection Diagnostics Market, by Test
- 6.1. Introduction
- 6.2. Antigen Detection Assays
- 6.3. Direct Fluorescent Antibody Tests
- 6.4. Imaging Tests
- 6.4.1. CT- Scan
- 6.4.2. X-ray
- 6.5. In Vitro Diagnostics (IVD) Tests
- 6.6. Nucleic Acid Amplification Tests
- 6.7. Rapid Diagnostic Tests
7. Respiratory Infection Diagnostics Market, by Disease
- 7.1. Introduction
- 7.2. Asthma
- 7.3. Chronic Obstructive Pulmonary Disease
- 7.4. Coronavirus Infections
- 7.5. Enterovirus
- 7.6. Influenza diseases
- 7.7. Lung Cancer
- 7.8. Pneumonia
- 7.9. Tuberculosis
- 7.10. Whooping Cough (Pertussis)
8. Respiratory Infection Diagnostics Market, by End-User
- 8.1. Introduction
- 8.2. Clinical Laboratories
- 8.3. Hospitals
9. Americas Respiratory Infection Diagnostics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Respiratory Infection Diagnostics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Respiratory Infection Diagnostics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Abbott Laboratories
- 2. AccuBioTech Co. Ltd.
- 3. Atomo Diagnostics Ltd.
- 4. Becton, Dickinson and Company
- 5. Bio-Rad Laboratories Inc.
- 6. bioMerieux SA
- 7. BIORON Diagnostics GmbH
- 8. Cardinal Health Inc.
- 9. Chembio Diagnostics, Inc.
- 10. F. Hoffmann-La Roche Ltd.
- 11. Hologic, Inc.
- 12. Merck KGaA
- 13. Meridian Bioscience Inc. by SD Biosensor
- 14. Quest Diagnostics Incorporated
- 15. Quidel Corporation
LIST OF FIGURES
- FIGURE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET RESEARCH PROCESS
- FIGURE 2. RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 13. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 15. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 21. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. RESPIRATORY INFECTION DIAGNOSTICS MARKET DYNAMICS
- TABLE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION ASSAYS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIRECT FLUORESCENT ANTIBODY TESTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CT- SCAN, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY X-RAY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS (IVD) TESTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENTEROVIRUS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 22. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA DISEASES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 23. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
- TABLE 24. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
- TABLE 25. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 26. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY WHOOPING COUGH (PERTUSSIS), BY REGION, 2018-2030 (USD MILLION)
- TABLE 27. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 28. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 29. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 30. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 31. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 32. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 33. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 34. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 35. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 36. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 37. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 38. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 39. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 40. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 41. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 42. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 43. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 44. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 45. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 46. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 47. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 48. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 49. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 50. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 51. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 52. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 53. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 54. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 55. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 56. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 57. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 58. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 59. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 60. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 61. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 62. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 63. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 64. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 65. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 66. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 67. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 68. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 69. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 70. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 71. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 72. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 73. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 74. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 75. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 76. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 77. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 78. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 79. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 80. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 81. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 82. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 83. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 84. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 85. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 86. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 87. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 88. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 89. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 90. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 91. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 92. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 93. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 94. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 95. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 96. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 97. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 98. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 99. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 100. TAIWAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 101. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 102. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 103. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 104. THAILAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 105. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 106. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 107. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 108. VIETNAM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 109. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 110. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 111. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 112. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 113. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 114. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 115. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 116. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 117. DENMARK RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 118. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 119. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 120. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 121. EGYPT RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 122. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 123. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 124. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 125. FINLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 126. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 127. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 128. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 129. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 130. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 131. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 132. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 133. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 134. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 135. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 136. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 137. ISRAEL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 138. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 139. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 140. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 141. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 142. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 143. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 144. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 145. NETHERLANDS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 146. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 147. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 148. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 149. NIGERIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 150. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 151. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 152. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 153. NORWAY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 154. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 155. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 156. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 157. POLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 158. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 159. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 160. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 161. QATAR RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 162. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 163. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 164. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 165. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 166. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 167. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 168. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 169. SAUDI ARABIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 170. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 171. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 172. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 173. SOUTH AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 174. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 175. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 176. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 177. SPAIN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 178. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 179. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 180. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 181. SWEDEN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 182. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 183. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 184. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 185. SWITZERLAND RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 186. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 187. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 188. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 189. TURKEY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 190. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 191. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 192. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 193. UNITED ARAB EMIRATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 194. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
- TABLE 195. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
- TABLE 196. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
- TABLE 197. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 198. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 199. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
